Pricing on Evidence: The Shift That Changes Every Downstream Decision

Your pricing is probably based on what a competitor charges, what a consultant recommended three years ago, and what your VP of Sales thought felt right at a particular moment. That combination is not a pricing strategy. It is accumulated guesswork dressed in a slide deck.

The evidence you need to price your product correctly already exists in your business. You are almost certainly not using it.

What It Actually Costs

Instinct-based pricing creates a specific pattern: your pricing feels roughly right because you are winning deals, but you cannot explain why you win at some price points and lose at others, and your average discount rate has been creeping upward for 18 months.

That creep is expensive. An upward drift of 3 percentage points in average discount rate over 18 months, from 17% to 20%, translates to $1.5M in lost realized revenue on a $50M annual recurring revenue (ARR) base. It happens without any single visible event. No one deal caused it. The signal is only visible in aggregate.

The teams that catch this pattern early do so because they measure pricing evidence continuously, not annually when the board asks why net revenue retention (NRR) has softened.

The Approach

Step 1: Run a price sensitivity analysis on your existing deal data.

Sort your last 18 months of closed deals by realized price per seat or per unit, whichever is your core value metric. Plot win rate against price per unit. You are looking for the inflection point where win rate drops materially. That is your current market ceiling. Your current list price relative to that ceiling tells you whether you are pricing too low, too high, or appropriately for your win rate targets.

Step 2: Run structured win/loss interviews on your last 15 competitive deals.

Ask one question in each interview: at what point in the evaluation process did price become a discussion point, and how did it affect the outcome? Classify each response: price was irrelevant, price was a factor, price was the deciding factor. If price was the deciding factor in more than 40% of losses, you have a pricing communication problem. If it was the deciding factor in more than 60%, you have a pricing level problem.

Step 3: Segment your expansion data by entry price point.

Customers who pay more at entry tend to expand more, not less. This runs counter to intuition but holds across most B2B SaaS categories. If your highest-priced segment has better NRR than your lowest-priced segment, you have evidence that your product is under-priced for your best customers. That is an opportunity.

Where This Breaks

A $36M ARR project management SaaS company had held their tier pricing flat for two years after a competitive pricing review showed they were roughly in line with three named competitors. The review used publicly listed prices, which none of the competitors actually transacted at.

Their win/loss data, if anyone had analyzed it, showed they were winning 74% of deals in mid-market and losing 58% of deals in enterprise. Not because of product. Because their enterprise tier was priced at $2,800 per seat annually when enterprise buyers were expecting a meaningful step up from their mid-market tier and finding the jump unconvincing.

Before evidence-based repricing: $36M ARR, 67% blended win rate, 91% NRR. Fourteen months after repricing enterprise tier 40% upward with outcome packaging: $48M ARR, 71% blended win rate (enterprise improved from 42% to 63%), 103% NRR.

Raising price increased win rate. The competitive pricing research had told them the opposite.

Next Actions This Week

Pull your last 20 closed-lost deals and answer one question for each: was price explicitly mentioned as a reason for the loss? If yes, was it that your price was too high or that your value justification was insufficient? These are different problems with different solutions. The first requires a pricing change. The second requires a sales motion change. Confusing them is expensive.

What does your actual deal data tell you about your pricing that your pricing deck does not?

Assess Your Commercial Health